Catalyst Event

Pfizer Inc (PFE) · Other

From KEDI U.S. Quality500 + Monthly 1% Premium Index(NTR) (KUSQL500P)

3/19/2026, 12:00:00 AM

OtherSentiment: Positive

On March 19, 2026, Pfizer announced that its combination therapy of TALZENNA plus XTANDI significantly improved radiographic progression-free survival in patients with a specific type of metastatic prostate cancer.

Korean Translation

2026년 3월 19일, 화이자는 탈제나(TALZENNA)와 엑스탄디(XTANDI) 병용 요법이 특정 유형의 전이성 전립선암 환자의 방사선학적 무진행 생존기간을 유의미하게 개선했다고 발표함.

Related Recent Events

View Full Timeline